期刊文献+

环氧化酶-2选择性抑制剂NS-398逆转HCT-8/FU细胞多药耐药及其机制探讨 被引量:1

Reversion effect of COX-2 selective inhibitor NS-398 on multi-drug resistance of HCT-8/FU cells and its mechanism
下载PDF
导出
摘要 目的观察环氧化酶-2(COX-2)选择性抑制剂NS-398对结肠癌细胞HCT-8/FU多药耐药(MDR)的逆转作用,并初步探讨其作用机制。方法通过CCK-8法检测NS-398对HCT-8/FU的耐药逆转倍数,应用免疫细胞化学法检测NS-398作用前后细胞膜P-gp表达情况,流式细胞术检测细胞早期凋亡。结果 NS-398作用HCT-8/FU细胞24 h后,细胞对5-FU的敏感性显著增加,浓度为10μmol/L和20μmol/L时耐药逆转倍数为3.55和10.73倍,呈现剂量依赖性,20μmol/L作用24 h后免疫细胞化学法检测P-gp表达减少,流式细胞术检测到NS-398 10μmol/L、20μmol/L作用24 h,细胞早期凋亡率分别为(11.95±0.325167)%及(21.49±0.690217)%,均验证了该细胞对5-FU重新恢复敏感性。结论环氧化酶-2选择性抑制剂NS-398可逆转HCT-8/FU细胞多药耐药,一定浓度范围内呈现剂量依赖关系,无毒剂量的NS-398亦可具有逆转耐药的作用,其机制可能通过抑制P-gp的表达及促进细胞凋亡起作用。 【Objective】 Observe the multi-drug resistance(MDR) reversal of cyclooxygenase-2(COX-2) selective inhibitor NS-398 on colon cancer cells HCT-8/FU,and explore its mechanism preliminarily.【Methods】 detect the reversal of multi-drug resistance on HCT-8/FU by NS-398 through the method of CCK-8,detect the expression of P-gp before and after the effect of NS-398 through the immunocytochemical method,detect the apoptosis by flow cytometry(FCM).【Results】 24 hours later after NS-398's effect on HCT-8/FU cells,the cells' sensitiveness to 5-FU increases remarkably;with the concentration of 10μmol/L and 20μmol/L,the reversal of multi-drug resistance are 3.55 and 10.73 respectively,and the dose dependent is presented;the expression of P-gp decreases after being effected by 20μmol/L for 24 hours through detection by immunocytochemical method;with the effect of NS-398 10μmol/L and 20μmol/L for 24 hours,apoptosis rate are 11.95±0.325167 % and 21.49±0.690217% respectively,which is detected by flow cytometry(FCM).They all verify the inhibition of 5-FU to cells.【Conclusion】 Cyclooxygenase-2 selective inhibitor NS-398 can reverse multi-drug resistance of HCT-8/FU cell,and within certain range of concentration,the dose dependent relationship is presented.Non-toxic NS-398 also has the function of reversal resistance and it plays its role by inhibiting the expression of P-gp and promoting the apoptosis.
机构地区 河北北方学院
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2011年第24期2945-2948,2951,共5页 China Journal of Modern Medicine
关键词 结肠癌 多药耐药 环氧化酶-2抑制剂 P-糖蛋白 Colorectal Carcinoma Multi-drug Resistant Cyclooxygenase-2 inhibitor P-glycoprotein
  • 相关文献

参考文献15

  • 1BARTOLINI G, ORLANDI M, PAPI A, et al. A search formultidrug re- sistance modulators: The effects of retinoids in human colon carcinoma cells[J]. In Vivo, 2006, 20(6A): 729-733.
  • 2NARDONE G, ROCCO A, VAIRA D, et al. Expression of COX-2, mPGE-synthase 1, MDR-I(P-gp), and Bel-xL: a molecular pathway of Hpylori-related gastric carcinogenesis [J]. J Pathol, 2004, 202 (3): 305-312.
  • 3MILELLA M, GELIBTER A, DICOSIMO S, et al. Pilot study of eele- coxib and in fusional 5-fluorouracil as second-line treatment for ad- vanced pancreatic carcinoma[J]. Cancer, 2004, 101(1): 133-138.
  • 4ALTORKI NK, KERESZTES RS, PORT JL, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative pa- clitaxel and carboplatin in early-stage non small-cell lung cancer [J]. J Clin Oncol. 2003.21(14): 2645-2650.
  • 5LABINACA R, MOSCONI S, CARASSINO MC. New strategies in colon cancer adjuvant therapy[J]. Annals of Oncology, 2006, 17(7): 51-54.
  • 6BARTOLINI G, ORLANDI M, PAPI A, et al. A search for mulfidrug resistance modulators: The effects of retinoids in human colon carcino- ma cells[J]. In Vivo, 2006, 20(6A): 729-733.
  • 7HYDE CA, MISSALIDIS S. Inhibition of araehidonie aeidme-tabolism and its implication on cell proliferation and Tumour-angiogenesis [J]. Int Immunopharmacol, 2009, 9(6): 701-715.
  • 8SPINELLA F, ROSANO L, DICASTRO V, et al. Endothelin-1 and en- dothelin-3 promote invasive behavior via hypo~a-inducible factor-1 (alpha)in human melanoma ceils [J]. Cancer Res, 2007, 67 (4): 1725-1734.
  • 9NARDONE G, ROCCO A, VAIRA D, et al. Expression of COX-2, mPGE-synthase 1, MDR-1 (P-gp), and Bel-xL: a molecular pathway of Hpylofi-related gastric eareinogenesis [J]. J Pathol, 2004, 202 (3): 305-312.
  • 10ALTORKI NK, KERESZTES RS, PORT JL, et al. Celecoxib, a selec- tive cyciooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non small-cell lung cancer [J]. J Clin Oncol, 2003, 21(14):2645-2650.

二级参考文献2

共引文献3

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部